STUDY DATES: 05/01/2019 – 03/31/2024
As many as 30% of older adults use a medication that increases the risk of Alzheimer’s disease and related dementias (ADRD), however no study has yet tested whether stopping anticholinergics in current users results in improved and sustained benefit on cognition.
This proposal will conduct a randomized trial to determine if a pharmacist-based, anticholinergic de-prescribing intervention improves cognition and lowers the risk of ADRD in primary care
older adults with subjective cognitive dysfunction. Safety measures for disease severity and quality of life will complement the cognitive outcomes in the 24 month duration of the study.